AR124018A1 - Inhibidores de péptidos de la proteína de fisión mitocondrial humana 1 y métodos de uso - Google Patents
Inhibidores de péptidos de la proteína de fisión mitocondrial humana 1 y métodos de usoInfo
- Publication number
- AR124018A1 AR124018A1 ARP210103090A ARP210103090A AR124018A1 AR 124018 A1 AR124018 A1 AR 124018A1 AR P210103090 A ARP210103090 A AR P210103090A AR P210103090 A ARP210103090 A AR P210103090A AR 124018 A1 AR124018 A1 AR 124018A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- peptide
- amino acids
- mitochondrial fission
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 230000004992 fission Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000002438 mitochondrial effect Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 101150075109 FIS1 gene Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000006492 vascular dysfunction Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación proporciona péptidos inhibidores de la proteína de fisión mitocondrial 1 (Fis1), polinucleótidos y vectores que codifican los péptidos, y métodos de uso de los péptidos para tratar enfermedades, incluidas arteriopatías y disfunción vascular asociadas con la diabetes de tipo 2. Reivindicación 1: Un péptido inhibidor de la actividad de la proteína de fisión mitocondrial 1 (Fis1) que comprende (a) una secuencia de aminoácidos de la SEQ ID nº 38 (XLPYPHZ) o una secuencia que tiene al menos 80% de identidad de secuencia con la SEQ ID nº 38, caracterizado porque X y Z pueden ser un péptido de 0 - 30 aminoácidos, opcionalmente de 1 - 20 aminoácidos. Reivindicación 2: El péptido inhibidor de la reivindicación 1 que comprende (a) una secuencia de aminoácidos que se selecciona de la SEQ ID nº 33 - 37 o una secuencia que tiene al menos un 80% de identidad secuencial respecto de la SEQ ID nº 33 - 37, caracterizado porque el péptido es de aproximadamente 5 - 50 aminoácidos de longitud, opcionalmente 5 - 30 aminoácidos de longitud. Reivindicación 3: El péptido inhibidor de una cualquiera de las reivindicaciones precedentes, caracterizado porque la secuencia de aminoácidos comprende (a) la SEQ ID nº 1 (SHKHDPLPYPHFLL) o una secuencia que tiene al menos 90% de identidad de secuencia con la SEQ ID nº 1, o una cualquiera de las SEQ ID nº 16 - 21, 26 y 29, o una secuencia que tiene un 90% de similitud con las SEQ ID nº 16 - 21, 26 y 29.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063110457P | 2020-11-06 | 2020-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR124018A1 true AR124018A1 (es) | 2023-02-01 |
Family
ID=81456767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210103090A AR124018A1 (es) | 2020-11-06 | 2021-11-08 | Inhibidores de péptidos de la proteína de fisión mitocondrial humana 1 y métodos de uso |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240010683A1 (es) |
EP (1) | EP4240393A1 (es) |
JP (1) | JP2023549131A (es) |
KR (1) | KR20230104243A (es) |
CN (1) | CN116964070A (es) |
AR (1) | AR124018A1 (es) |
AU (1) | AU2021373879A1 (es) |
CA (1) | CA3200841A1 (es) |
TW (1) | TW202233648A (es) |
WO (1) | WO2022099123A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ547671A (en) * | 2003-12-05 | 2009-10-30 | Univ Northwestern | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
WO2008020778A1 (fr) * | 2006-07-31 | 2008-02-21 | Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) | Famille de peptides dotés d'une activité analgésique |
WO2012158624A2 (en) * | 2011-05-13 | 2012-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of mitochondrial fission and methods of use thereof |
US9526762B1 (en) * | 2013-08-09 | 2016-12-27 | William Marsh Rice University | Multidomain peptides for promoting angiogenesis |
US20210032669A1 (en) * | 2018-02-27 | 2021-02-04 | Manus Bio, Inc. | Microbial production of triterpenoids including mogrosides |
-
2021
- 2021-11-08 AU AU2021373879A patent/AU2021373879A1/en active Pending
- 2021-11-08 KR KR1020237018963A patent/KR20230104243A/ko unknown
- 2021-11-08 CN CN202180075040.0A patent/CN116964070A/zh active Pending
- 2021-11-08 EP EP21890231.0A patent/EP4240393A1/en active Pending
- 2021-11-08 JP JP2023527376A patent/JP2023549131A/ja active Pending
- 2021-11-08 TW TW110141577A patent/TW202233648A/zh unknown
- 2021-11-08 CA CA3200841A patent/CA3200841A1/en active Pending
- 2021-11-08 US US18/252,073 patent/US20240010683A1/en active Pending
- 2021-11-08 WO PCT/US2021/058437 patent/WO2022099123A1/en active Application Filing
- 2021-11-08 AR ARP210103090A patent/AR124018A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021373879A9 (en) | 2024-09-26 |
EP4240393A1 (en) | 2023-09-13 |
TW202233648A (zh) | 2022-09-01 |
US20240010683A1 (en) | 2024-01-11 |
AU2021373879A1 (en) | 2023-06-08 |
WO2022099123A1 (en) | 2022-05-12 |
KR20230104243A (ko) | 2023-07-07 |
JP2023549131A (ja) | 2023-11-22 |
CA3200841A1 (en) | 2022-05-12 |
CN116964070A (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tatemoto et al. | Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides | |
JP5002603B2 (ja) | 新規なペプチド及びこれの用途 | |
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
ES2062514T3 (es) | Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento. | |
CO5640064A2 (es) | Citomodilacion de peptidos para tratar cistitis intersticial | |
DK165988B (da) | Modificerede egliner b og c, deres anvendelse som proteaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende de modificerede egliner b og c | |
ATE278708T1 (de) | Conotoxin peptid pviia | |
AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
DK0479912T3 (da) | Fremgangsmåde til hæmning af N-endereglens forløb i levende celler | |
CO2021017664A2 (es) | Péptidos | |
EA200000378A1 (ru) | Усеченные по амино-концу мср-2 как антагонисты хемокинов | |
AR124018A1 (es) | Inhibidores de péptidos de la proteína de fisión mitocondrial humana 1 y métodos de uso | |
PE20230783A1 (es) | Proteinas actrii para el tratamiento de la hipertension pulmonar | |
AR023481A1 (es) | Vectores que contienen un gen que codifica cd40 y/o cd40l bajo el control de un promotor citoquina-inducible, metodos para su produccion y usos de losmismos | |
Li et al. | Characterization of bradykinin-related peptides generated in the plasma of six sarcopterygian species (African lungfish, amphiuma, coachwhip, bullsnake, gila monster, and Gray's monitor) | |
Conlon et al. | Purification of a vasoactive peptide related to lysyl‐bradykinin from trout plasma | |
BR0011954A (pt) | Inibidores da integrina alfavbeta6 | |
NO20034146D0 (no) | Syntetiske peptider og fremgangsmåte for forebyggende og terapeutisk anvendelse i kreftinvasjon og metastase | |
JPH06107682A (ja) | バッカリン様軟体動物神経ペプチド | |
AR016939A1 (es) | Metodo para seleccionar una vid transgenica o componente de una vid que tiene una resistencia aumentada a la enfermedad de ''fanleaf'' y una celulade planta transformada con un vector de expresion. | |
US5514775A (en) | Chromogranin peptides | |
EA200100314A1 (ru) | Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины | |
WO1993021217A1 (en) | Invertebrate peptides | |
Altstein et al. | Structure—Function Relationship of PBAN/MRCH | |
KR20080039878A (ko) | 트롬보스폰딘-1 유래 펩티드 및 치료 방법 |